The latest update is out from Bluechiip Limited ( (AU:BCT) ).
Bluechiip Limited has announced that its shares will remain suspended until the company lodges its full year 2024 audited accounts and Annual Report with the ASX. The company is undergoing a strategic review with a focus on securing partnerships and refinancing, while dealing with unforeseen challenges such as the hospitalization of its Financial Controller. A significant development includes the BioLife deal, which is expected to drive sales revenue in 2025. The company has established a solid platform with numerous large pharmaceutical companies and aims to reach cash-flow break-even by expanding its customer base.
More about Bluechiip Limited
Bluechiip Limited is a company specializing in advanced sample management solutions, particularly within cryogenic environments. Their technology is a MEMS-based wireless tracking solution for biological samples, which represents a significant advancement over traditional tracking methods like labels and barcodes. The company’s products have applications across various sectors including healthcare, pathology, and cold-chain logistics.
Current Market Cap: $12.89M
For a thorough assessment of BCT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com